Mammalian Target of Rapamycin and Insulin Resistance

雷帕霉素和胰岛素抵抗的哺乳动物靶标

基本信息

  • 批准号:
    7139915
  • 负责人:
  • 金额:
    $ 14.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-03-01 至 2008-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Approximately 18 million Americans have diabetes resulting in an estimated $92 billion in direct medical costs per year. Type 2 diabetes mellitus accounts for approximately 90-95% of all diabetes. Although the cause of type 2 diabetes is unknown, one common factor of the disease is insulin resistance. Since skeletal muscle is the primary site for insulin-mediated glucose disposal, insulin resistance is thought to be due, in part, to a defect in skeletal muscle's ability to respond appropriately to increases in circulating insulin. The goal of this proposal is to determine whether or not the mammalian target of rapamycin (mTOR) plays a role in the development of skeletal muscle insulin resistance. mTOR is a nutrient sensitive and insulin responsive serine/threonine kinase that controls mRNA translation and cellular growth. Recent cell culture studies have demonstrated that activating the mTOR pathway inhibits insulin signal transduction and promotes insulin resistance. Our first hypothesis is that activating mTOR-mediated signal transduction will produce insulin resistance in skeletal muscle, a process that will be reversed by rapamycin, a highly specific inhibitor of mTOR. Specific aim #1 will examine the effects of mTOR-mediated signaling on insulin action in skeletal muscle. We will determine if incubating muscle with amino acids produces insulin resistance by an mTOR dependent serine phosphorylation of the insulin receptor substrate-1 (IRS-1). Serine phosphorylation of IRS-1 is thought to promote insulin resistance by decreasing IRS-1 tyrosine phoshorylation and promoting IRS-1 degradation. We will also examine the effects of activating mTOR with amino acids on insulin's ability to promote the phosphorylation of protein kinase B (PKB) on Thr308 and Ser473. Phosphorylation of PKB on these sites is necessary for full kinase activity and the stimulation of glucose transport. Our preliminary data indicate activating mTOR signaling reduces insulin-stimulated PKB phosphorylation on Ser473 in skeletal muscle, a process that is abolished by rapamycin. Finally, specific aim #1 will determine if activating mTOR signaling with amino acids decreases insulin's ability to recruit GLUT4 to the cell surface and stimulate glucose transport in skeletal muscle. Our second hypothesis is that the hyperinsulinemia associated with diet-induced insulin resistance constitutively activates mTOR. Specific aim #2 will examine the phosphorylation of mTOR on Ser2448 in muscles from mice subjected to a high fat diet compared to controls. Ser2448 is a site in mTOR whose phosphorylation is associated with increased kinase activity. The results from these studies will provide new insights into factors that play a role in the development of insulin resistance and possibly lead to the use of mTOR inhibitors as novel treatments for type 2 diabetes.
描述(由申请人提供):大约1800万美国人患有糖尿病,每年直接医疗费用估计为920亿美元。2型糖尿病约占所有糖尿病的90%-95%。虽然2型糖尿病的病因尚不清楚,但该疾病的一个共同因素是胰岛素抵抗。由于骨骼肌是胰岛素介导的葡萄糖处理的主要部位,胰岛素抵抗被认为在一定程度上是由于骨骼肌对循环中胰岛素增加做出适当反应的能力缺陷。这项建议的目的是确定哺乳动物的雷帕霉素靶点(MTOR)是否在骨骼肌胰岛素抵抗的发展中发挥作用。MTOR是一种营养敏感和胰岛素敏感的丝氨酸/苏氨酸激酶,控制着mRNA的翻译和细胞的生长。最近的细胞培养研究表明,激活mTOR通路可以抑制胰岛素信号转导,促进胰岛素抵抗。我们的第一个假设是,激活mTOR介导的信号转导将在骨骼肌中产生胰岛素抵抗,这一过程将被mTOR的高度特异性抑制剂雷帕霉素逆转。具体目标#1将研究mTOR介导的信号对骨骼肌中胰岛素作用的影响。我们将通过依赖mTOR的丝氨酸磷酸化胰岛素受体底物-1(IRS-1)来确定与氨基酸孵育的肌肉是否产生胰岛素抵抗。IRS-1的丝氨酸磷酸化被认为通过减少IRS-1的酪氨酸磷酸化和促进IRS-1的降解来促进胰岛素抵抗。我们还将研究氨基酸激活mTOR对胰岛素促进Thr308和Ser473上蛋白激酶B(PKB)磷酸化能力的影响。这些位点上的PKB的磷酸化是充分的激酶活性和刺激葡萄糖运输所必需的。我们的初步数据表明,激活mTOR信号可减少胰岛素刺激的骨骼肌Ser473上PKB的磷酸化,这一过程可被雷帕霉素取消。最后,特定的目标#1将确定用氨基酸激活mTOR信号是否会降低胰岛素将GLUT4募集到细胞表面并刺激骨骼肌中葡萄糖运输的能力。我们的第二个假设是,与饮食诱导的胰岛素抵抗相关的高胰岛素血症结构性地激活了mTOR。特定目标#2将检测与对照组相比,高脂肪饮食小鼠肌肉中mTOR在Ser2448上的磷酸化。Ser2448是mTOR中的一个位点,它的磷酸化与激酶活性的增加有关。这些研究的结果将为在胰岛素抵抗的发展中发挥作用的因素提供新的见解,并可能导致将mTOR抑制剂用作治疗2型糖尿病的新疗法。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS H REYNOLDS其他文献

THOMAS H REYNOLDS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS H REYNOLDS', 18)}}的其他基金

Age-Related Obesity and Healthspan: Identifying Interventions and Mechanisms
与年龄相关的肥胖和健康寿命:确定干预措施和机制
  • 批准号:
    9171143
  • 财政年份:
    2016
  • 资助金额:
    $ 14.11万
  • 项目类别:
Rev-ERBa Regulates Mitochondrial Biogenesis, Adiposity, and Insulin Action
Rev-ERBa 调节线粒体生物发生、肥胖和胰岛素作用
  • 批准号:
    8035783
  • 财政年份:
    2010
  • 资助金额:
    $ 14.11万
  • 项目类别:
Age Related Insulin Resistance, Akt/PKB, and Skeletal Muscle Proteolysis
年龄相关的胰岛素抵抗、Akt/PKB 和骨骼肌蛋白水解
  • 批准号:
    7363050
  • 财政年份:
    2007
  • 资助金额:
    $ 14.11万
  • 项目类别:
Mammalian Target of Rapamycin and Insulin Resistance
雷帕霉素和胰岛素抵抗的哺乳动物靶标
  • 批准号:
    6897719
  • 财政年份:
    2005
  • 资助金额:
    $ 14.11万
  • 项目类别:

相似海外基金

Asymmetric Single-Chain MspA nanopores for electroosmotic stretching and sequencing proteins
用于电渗拉伸和蛋白质测序的不对称单链 MspA 纳米孔
  • 批准号:
    10646810
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
Exploring the Role of Nitrogen Metabolism in Cancer
探索氮代谢在癌症中的作用
  • 批准号:
    10737792
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
Discovery of neoepitope immunotherapeutic targets in diffuse pediatric high-grade gliomas
弥漫性儿童高级别胶质瘤中新表位免疫治疗靶点的发现
  • 批准号:
    10774404
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
Detecting cell to cell contacts in zebrafish with a synthetic receptor methodology
使用合成受体方法检测斑马鱼的细胞与细胞接触
  • 批准号:
    10645331
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
A novel peptide assay for hepcidin clinical monitoring
一种用于铁调素临床监测的新型肽测定方法
  • 批准号:
    10698746
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
基于肽酶刺激的新方法用于靶向耐药性乳腺癌
  • 批准号:
    10713648
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
醋酸鲁沙来肽 (TP508) 对放射诱发的角膜病变的缓解作用
  • 批准号:
    10605739
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
Identifying the Molecular Function of the Y-linked Mouse Zinc Finger Proteins ZFY1 and ZFY2
鉴定 Y 连锁小鼠锌指蛋白 ZFY1 和 ZFY2 的分子功能
  • 批准号:
    10749409
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
Discovery and Roles of In Situ Islet Neoantigens in Human Type 1 Diabetes
原位胰岛新抗原在人类 1 型糖尿病中的发现及其作用
  • 批准号:
    10589578
  • 财政年份:
    2023
  • 资助金额:
    $ 14.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了